Agreement with IRRI marks Pairwise's third CGIAR partnership, enabling the research institute to use Fulcrum® genome editing technology to develop higher-yielding, more nutritious rice varieties that ...

New Zealand First leader Winston Peters has sought to reassure a crowd opposing the Gene Technology Bill that his party will ...

KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Here’s the latest company planning for gene-edited babies The news: A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Genetic testing is transforming healthcare through personalized medicine, enabling early diagnosis, targeted treatments, and a future of more precise, patient-centered care.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Discover ARK Invest's latest portfolio shifts into healthcare, crypto, and finance stocks. See key buys and sells by Cathie Wood.